Sanoj Punnen, MD, MAS, specifies how multimodal detection options for prostate cancer could improve and personalize diagnosis.
Wolfgang Weber, MD, reviews a half-decade of progress in the field of prostate cancer imaging and theranostics.
Steven S. Raman, MD, explains how MRI aids in prostate cancer staging, diagnosis, follow-up, treatment planning, and image-guided treatment.
Phillip J. Koo, MD, discusses clinical, research, and educational targets advancing nuclear medicine’s role in prostate cancer treatment.
Laurence Klotz, MD, Professor of Surgery at the University of Toronto, discusses the miR Scientific Sentinel Assay.
Thomas J. Polascik, MD, FACS, Professor of Urology at Duke University Medical Center, discusses the effectiveness of focal therapy for prostate cancer as an alternative to radical therapy.
Wolfgang Weber, MD, Professor and Chair of the Department of Nuclear Medicine at the Technical University of Munich in Germany, discusses the changes in molecular imaging over the last 7 years and their impact on staging and re-staging of prostate cancer. Dr. Weber discusses how PSMA PET imaging works by binding with the ligands of antigens present in cells affected by prostate cancer.
Masoom Haider, MD, provides an overview of the current state of multiparametric MRI, especially in the setting of biopsy-naive patients with elevated PSA levels. He then describes an MRI-directed biopsy pathway and how to integrate it into prostate cancer care.
Gerald L. Andriole, Jr., MD, discusses the unmet need for precise imaging of biochemical recurrent prostate cancer. He reviews data on imaging agents, especially 18F-fluciclovine PET/CT, ¹¹C-choline PET/CT, and 68Ga-PSMA-11, and deliberates on the impact of imaging-guided treatment changes on patient outcomes.
Michael J. Zelefsky, MD, argues that combining stereotactic body radiation therapy (SBRT) with low-dose rate brachytherapy can help to reduce the morbidities of combined-modality radiotherapy.
Jason A. Efstathiou, MD, DPhil, emphasizes the need for continued clinical trials to refine therapy options for high-risk and locally advanced prostate cancer patients. He reviews six major considerations regarding the current state of external beam radiation therapy (EBRT) for the treatment of high-risk disease.
Ryan S. Hsi, MD, reviews findings from abstracts presented at the American Urological Association's 2019 Annual Meeting on the use of high-resolution microultrasound in detecting prostate cancer.